Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Press Releases
2688 Articles Available
1
112
Can't find what you're looking for? Try our
advanced search
.
FDA Authorization
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
PR-M11-20-022
Microfluids
Enhancing Interferometry with Dolomite’s Mitos Dropix
PR-M11-20-024
COVID-19 Vaccine
Russia's Sputnik V COVID-19 Vaccine Is 91% Effective
PR-M11-20-023
Antibodies
Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
PR-M11-20-022
Clinical Study
Iron Oxides Enhance Protection Against Skin Damage
PR-M11-20-021
COVID-19
Cue’s Molecular, Point-of-Care COVID-19 Tests Deployed to Five States in HHS and DOD Pilot Program
PR-M11-20-020
Capacity Expansion
WuXi Advanced Therapies Expands Philadelphia Campus with New State-of-the-Art Testing Laboratory
PR-M11-20-019
M&A
AbCellera Expands Technology Stack with Acquisition of Trianni for $90 Million
PR-M11-20-018
Financing
Syncona Founds Purespring with £45m in Series A Financing
PR-M11-20-017
Investment
SEQENS Invests in New Technologies
PR-M11-20-015
Proof-of-Concept Trial
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
PR-M11-20-014
Clinical Trials
The Bristol Myers Squibb Foundation and National Medical Fellowships Launch $100 Million Program to Help Increase Diversity and Inclusion in Clinical Trials
PR-M11-20-015
COVID-19 Testing Kit
Celltrion to Launch Both Antigen and Antibody Testing Kits in the U.S.
PR-M11-20-016
Financing
Nereid Therapeutics Raises $50M in Series A Funding
PR-M11-20-014
COVID-19 Vaccine
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
PR-M11-20-013
Fast Track
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
PR-M11-20-012
Cannabinoids
BIOMEDICAN Announces Successful Biosynthesis and Large-Scale Production of Rare Cannabinoids CBG/CBGA
PR-M11-20-010
Expanded Services
WuXi Advanced Therapies Expands Services to Include High-Quality and Cost-Effective R&D and GMP Plasmid DNA
PR-M11-20-011
Cancer Vaccine
Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program
PR-M11-20-009
M&A
Merck to Acquire VelosBio
PR-M11-20-010
Fast Track
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
PR-M11-20-008
COVID-19
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
PR-M11-20-007
Novartis Announces Collaboration with Molecular Partners to Develop Two DARPin Therapies for Potential Use Against COVID-19
PR-M11-20-006
COVID-19 Clinical Trials
NeuroRx and Relief Therapeutics Announce Continuation of RLF-100 Trial for the Treatment of COVID-19 Respiratory Failure
PR-M11-20-005
1
112
»
